Cancer drug developer ChemoCentryx cancels IPO
Mountain View, Calif.-based biotech firm ChemoCentryx announced that it withdrew its filing to go public, citing (as per usual) unfavorable market conditions. The company, which develops drugs to treat cancer and autoimmune ailments like Crohn’s disease, raked in $50 million from its partner GlaxoSmithKline just… Continue Reading
ChemoCentryx raises $50M, eyes bleak IPO landscape for biotech
ChemoCentryx Inc., a biotech company that develops drugs to treat immune system ailments, got a $50 million payday from partner and major shareholder GlaxoSmithKline PLC in August. The plan last November was to raise $57.5 million through an IPO, but with only four VC-funded health… Continue Reading
IPOs: Biotech ChemoCentryx and specialty-pharma Xanodyne head for the public market
ChemoCentryx files for $58M IPO to fund autoimmune, inflammation drug — Mountain View, Calif.-based ChemoCentryx, a biotech focused on new small-molecule drugs that affect a class of biochemical signals known as chemokines, filed to raise $57.5 million in an initial offering. The company’s SEC filing… Continue Reading
Life sciences briefing: Monday, Nov. 12, 2007
(UPDATED: See below.)
Featured companies: Anaptys Biosciences, Arterial Remodeling Technologies, Cambria Biosciences, CaseNet, ChemoCentryx, Ensemble Discovery, MediQuest, Piedmont Pharmaceuticals, Raven Biotechnologies, Sensys Medical, Verus Pharmaceuticals, Xanodyne Pharmaceuticals
UPDATED: Expanded items on Anaptys, Arterial Remodeling, Raven Biotech, Sensys and MediQuest. Moved ChemoCentryx and Xanodyne to a separate item.
Antibody-drug maker Raven Biotech… Continue Reading
ChemoCentryx, autoimmune disease drug co., raises $29.84M
ChemoCentryx, a Mountain View, Calif. developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has raised $29.84 million in forth round of funding, according to a regulatory filing cited by PE Week. Glaxo Group Ltd. was joined by existing investors, including Alta Partners,… Continue Reading